BACKGROUND: Specific blockade of T cell costimulation pathway is a promising immunomodulatory approach being developed to replace our current clinical immunosuppression therapies. The goal of this study is to compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway. METHODS: Cynomolgus monkey heterotopic cardiac allograft recipients were treated with either IDEC-131 (humanized αCD154, n = 9), 5C8H1 (mouse-human chimeric αCD154, n = 5), or 2C10R4 (mouse-rhesus chimeric αCD40, n = 6) monotherapy using a consistent, comparable dosing regimen for 3 months after transplant. RESULTS: Relative to the previously reported IDEC-131-treated allografts, median survival time (35 ± 31 days) was significantly prolonged in both 5C8H1-treated (142 ± 26, P < 0.002) and 2C10R4-treated (124 ± 37, P < 0.020) allografts. IDEC-131-treated grafts had higher cardiac allograft vasculopathy severity scores during treatment relative to either 5C8H1 (P = 0.008) or 2C10R4 (P = 0.0002). Both 5C8H1 (5 of 5 animals, P = 0.02) and 2C10R4 (6/6, P = 0.007), but not IDEC-131 (2/9), completely attenuated IgM antidonor alloantibody (alloAb) production during treatment; 5C8H1 (5/5) more consistently attenuated IgG alloAb production compared to 2C10R4 (4/6) and IDEC-131 (0/9). All evaluable explanted grafts experienced antibody-mediated rejection. Only 2C10R4-treated animals exhibited a modest, transient drop in CD20 lymphocytes from baseline at day 14 after transplant (-457 ± 152 cells/μL) compared with 5C8H1-treated animals (16 ± 25, P = 0.037), and the resurgent B cells were primarily of a naive phenotype. CONCLUSIONS: In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunomodulatory treatment than 5C8H1 or 2C10R4, which have similar efficacy to prolong graft survival and to delay cardiac allograft vasculopathy development and antidonor alloAb production during treatment.
BACKGROUND: Specific blockade of T cell costimulation pathway is a promising immunomodulatory approach being developed to replace our current clinical immunosuppression therapies. The goal of this study is to compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 T cell costimulation pathway. METHODS:Cynomolgus monkey heterotopic cardiac allograft recipients were treated with either IDEC-131 (humanized αCD154, n = 9), 5C8H1 (mouse-human chimeric αCD154, n = 5), or 2C10R4 (mouse-rhesus chimeric αCD40, n = 6) monotherapy using a consistent, comparable dosing regimen for 3 months after transplant. RESULTS: Relative to the previously reported IDEC-131-treated allografts, median survival time (35 ± 31 days) was significantly prolonged in both 5C8H1-treated (142 ± 26, P < 0.002) and 2C10R4-treated (124 ± 37, P < 0.020) allografts. IDEC-131-treated grafts had higher cardiac allograft vasculopathy severity scores during treatment relative to either 5C8H1 (P = 0.008) or 2C10R4 (P = 0.0002). Both 5C8H1 (5 of 5 animals, P = 0.02) and 2C10R4 (6/6, P = 0.007), but not IDEC-131 (2/9), completely attenuated IgM antidonor alloantibody (alloAb) production during treatment; 5C8H1 (5/5) more consistently attenuated IgG alloAb production compared to 2C10R4 (4/6) and IDEC-131 (0/9). All evaluable explanted grafts experienced antibody-mediated rejection. Only 2C10R4-treated animals exhibited a modest, transient drop in CD20 lymphocytes from baseline at day 14 after transplant (-457 ± 152 cells/μL) compared with 5C8H1-treated animals (16 ± 25, P = 0.037), and the resurgent B cells were primarily of a naive phenotype. CONCLUSIONS: In this model, CD154/CD40 axis blockade using IDEC-131 is an inferior immunomodulatory treatment than 5C8H1 or 2C10R4, which have similar efficacy to prolong graft survival and to delay cardiac allograft vasculopathy development and antidonor alloAb production during treatment.
Authors: E A Elster; H Xu; D K Tadaki; S Montgomery; L C Burkly; J D Berning; R E Baumgartner; F Cruzata; R Marx; D M Harlan; A D Kirk Journal: Transplantation Date: 2001-11-15 Impact factor: 4.939
Authors: C S Cho; L C Burkly; J H Fechner ; A D Kirk; T D Oberley; Y Dong; K G Brunner; D Peters; C N Tenhoor; K Nadeau; G Yagci; N Ishido; J M Schultz; M Tsuchida; M M Hamawy; S J Knechtle Journal: Transplantation Date: 2001-08-27 Impact factor: 4.939
Authors: Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham Journal: J Heart Lung Transplant Date: 2005-06-20 Impact factor: 10.247
Authors: K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips Journal: Proc Natl Acad Sci U S A Date: 2003-09-30 Impact factor: 11.205
Authors: James E Crowe; Edith C Sannella; Steffen Pfeiffer; George L Zorn; Agnes Azimzadeh; Roland Newman; Geraldine G Miller; Richard N Pierson Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: Ichiro Koyama; Tatsuo Kawai; David Andrews; Svetlan Boskovic; Ognjenka Nadazdin; Siew Lin Wee; Hiroshi Sogawa; Dong-Li Wu; R Neal Smith; Robert B Colvin; David H Sachs; A Benedict Cosimi Journal: Transplantation Date: 2004-02-15 Impact factor: 4.939
Authors: Stuart J Knechtle; Julia M Shaw; Bernhard J Hering; Kristy Kraemer; Joren C Madsen Journal: Sci Transl Med Date: 2019-07-10 Impact factor: 17.956
Authors: Zachary Fitch; Robin Schmitz; Jean Kwun; Bernhard Hering; Joren Madsen; Stuart J Knechtle Journal: Transplant Rev (Orlando) Date: 2019-04-05 Impact factor: 3.943
Authors: Tianshu Zhang; Agnes M Azimzadeh; Wenji Sun; Natalie A O'Neill; Evelyn Sievert; Emily Bergbower; Gheorghe Braileanu; Lars Burdorf; Xiangfei Cheng; Thomas Monahan; Siamak Dahi; Donald G Harris; Elana Rybak; Emily Welty; Anthony Kronfli; Chris Avon; Richard N Pierson Journal: Transplantation Date: 2018-03 Impact factor: 5.385
Authors: Natalie A O'Neill; Tianshu Zhang; Gheorghe Braileanu; Xiangfei Cheng; Alena Hershfeld; Wenji Sun; Keith A Reimann; Sia Dahi; Natalia Kubicki; Wessam Hassanein; Christopher Laird; Arielle Cimeno; Agnes M Azimzadeh; Richard N Pierson Journal: Transplant Direct Date: 2018-02-02